REPLIMUNE GROUP, INC. Long-Term Debt
REPLIMUNE GROUP, INC. (REPL) had Long-Term Debt of $84.11 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt and Lease Obligation
us-gaap:LongTermDebtNoncurrent · last filed 2026-08-14
- 2026-06-30: Long-term Debt, Excluding Current Maturities $84.11M.
- 2026-03-31: Long-term Debt, Excluding Current Maturities $83.31M.
- 2025-12-31: Long-term Debt, Excluding Current Maturities $47.63M.
- 2025-09-30: Long-term Debt, Excluding Current Maturities $47.21M.
| Period end | Long-term Debt, Excluding Current Maturities |
|---|---|
| 2026-06-30 | $84.11M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $83.31M 10-Q · filed 2026-08-14 |
| 2025-12-31 | $47.63M 10-Q · filed 2026-02-03 |
| 2025-09-30 | $47.21M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $46.79M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $46.38M 10-K · filed 2026-06-29 |
| 2024-12-31 | $45.96M 10-Q · filed 2025-02-12 |
| 2024-09-30 | $45.57M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $45.19M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $44.81M 10-K · filed 2025-05-22 |
| 2023-03-31 | $28.65M 10-K · filed 2024-05-16 |
| 2022-03-31 | $0.00 10-K · filed 2023-05-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |